Phase 3CompletedAge-related condition
Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder
- Sponsor
- Alza Corporation, DE, USA (Industry)
- Enrollment
- 790 enrolled
- Conditions
- Urinary Incontinence
- Interventions
- oxybutynin chloride
- Ages
- adults, older adults
- Registry
- NCT00293839
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.
Primary outcomes
- The number of weekly urge urinary incontinence (Urge-UI) episodes at week 12, adjusted for the baseline value
History
Last registry update
Registered
Study completion